Date: 2014-01-09
Type of information: Licensing agreement
Compound: live attenuated Bordetella pertussis vaccine technology, including BPZE1
Company: ILiAD Biotechnologies (USA) Inserm (France) Inserm Transfert (France) Institut Pasteur de Lille (France)
Therapeutic area: Infectious diseases
Type agreement: collaboration
licensing
Action mechanism: vaccine
Disease: Bordetella pertussis infection
Details: * On January 9, 2014, ILiAD Biotechnologies, the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille (IPL) have announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore1 and National University of Ireland Maynooth. Building on publication in the journal PLOS One (“A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; […]”, Jan. 8, 2013), which suggests that BPZE1 is safe in healthy adults and can induce immune responses targeting Bordetella pertussis, ILiAD, Inserm and IPL now intend to optimize and advance the BPZE technology in preparation for future clinical studies.
Financial terms: Financial details of these agreements remain confidential.
Latest news:
